Chloramphenicol: is old really gold?
P. Mathur,B. Behera,D. Chaturvedi,M. Misra
2010-09-01
Abstract:Polymyxin B and colistin (Polymyxin E) is already being tried clinically in a select population as a life-saving antimicrobial. We evaluated the susceptibility of chloramphenicol against multi-drug-resistant Gram-negative bacteria (defined as resistant to at last two different classes of antimicrobials) at our hospital, which is a level-I trauma care centre of AIIMS hospital, India. A total of 1037 consecutive, MDR Gram negative bacterial isolates obtained from clinical samples of trauma patients admitted to the ICUs were screened for chloramphenicol susceptibility by the disc diffusion method as per the CLSI guidelines. 2 Of these, 368 (35%) were from respiratory samples, 214 (20%) from urine, 181 (17%) from blood, 160 (15%) from sterile fluids, 89 (8%) from pus and 25 (2%) from tips. Of the 1037 isolates, 292 (28%) were Acinetobacter baumannii, 287 (27%) were Pseudomonas aeruginosa, 199 (19%) were Klebsiella pneumoniae, 106 (10%) were E coli, 73 (7%) were Enterobacter cloacae, 29 (3%) were Proteus mirabilis, 19 (2%) were Stenotrophomonas maltophilia, 17 (1%) were Burkholderia cepacia, 8 (0.7%) were Morganella morgannii, 4 (0.4%) were Citrobacter diversus, two (0.2%) were Providencia rettgeri and one was Salmonella Typhi. For chloramphenicol, isolates with a zone diameter ≤ 12 mm were considered to be resistant, those having a zone diameter of 13-17 mm were intermediate, and those with a zone diameter of ≥ 18 mm were sensitive. 2 Only 155 of the 1037 isolates (15%) were sensitive to chloramphenicol. Thus, 20 (7%) isolates of A. baumannii, 24 (8%) P. aeruginosa, 54 (27%) K. pneumoniae, 34 (32%) E. coli, 17 (23%) E. cloacae, 4 (14%) Proteus Spp and one each of S. maltophilia and B. cepacia were chloramphenicol susceptible. The emergence of multidrug-resistant microorganisms has led some clinicians to reconsider the use of chloramphenicol. Several recent studies have documented a 90-95% re-emergence of chloramphenicol susceptibility among Salmonella enterica serotype typhi isolates in North India. 3, 4 Chloramphenicol is still being used as first line empiric treatment of acute bacterial meningitis and acute severe pneumonia in developing countries. A recent multicenter randomized control trail (SPEAR study), conducted in children aged 2-59 months with severe pneumonia within tertiary care hospitals in Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, and Zambia, advocated injectable ampiciliin plus gentamicin instead of injectable chloramphenicol in low resource settings. 5 Over the past decade, resistance to chloramphenicol among meningitis pathogens has become a major problem in many developing countries. In a recent